Vertex Pharmaceuticals Incorporated
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Vertex Pharmaceuticals Incorporated (VRTX), headquartered in Boston, Massachusetts and founded in 1989, develops, manufactures and commercializes transformative medicines for serious diseases, with a primary focus on cystic fibrosis, sickle cell disease, beta thalassemia and emerging areas including pain, kidney disease and type 1 diabetes; its portfolio features the CFTR modulators TRIKAFTA/KAFTRIO, ALYFTREK, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO, the CRISPR/Cas9 gene-edited therapy CASGEVY (co-developed with CRISPR Therapeutics), the non-opioid NaV1.7 pain treatment JOURNAVX/suzetrigine, and investigational assets such as povetacicept (for IgA nephropathy and other autoimmune kidney diseases), inaxaplin (for APOL1-mediated kidney disease), VX-407 (for autosomal dominant polycystic kidney disease), VX-522 (CFTR mRNA therapy with Moderna), VX-880/VX-264 (stem cell therapies for type 1 diabetes) and VX-993 (next-generation pain candidate); the company operates research facilities in San Diego, California and Milton Park, Oxfordshire, UK, with commercial presence across North America, Europe, Australia, Asia and the Middle East. In recent developments, Vertex completed its $4.9 billion acquisition of Alpine Immune Sciences in 2024 to secure povetacicept, entered an exclusive collaboration with Ono Pharmaceutical in June 2025 for povetacicept commercialization in Japan and South Korea (building on a prior deal with Zai Lab), launched ALYFTREK in the US and began European reimbursement efforts in England, Germany and Denmark, advanced CASGEVY and JOURNAVX launches with expanding US coverage including major PBMs and hospital networks, completed Phase 3 enrollment for povetacicept in IgA nephropathy (targeting accelerated US approval in H1 2026), initiated VX-407 Phase 2 proof-of-concept for ADPKD, progressed VX-522 Phase 1/2 data readout in H1 2025 and discontinued standalone development of an experimental pain drug following mid-stage failure while prioritizing suzertrigine/JOURNAVX expansion. Vertex reported Q3 2025 total revenues of $3.08 billion (up 11% year-over-year), driven by CF franchise growth, early new product contributions and favorable US pricing, with full-year 2025 guidance refined to $11.9-12.0 billion.
Company News
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy?
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Vertex Appoints Daniel Brennan to its Board of Directors
3,678 Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Banque Pictet & Cie SA
Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now?
Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts
Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders
Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma
Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know
Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference
Vertex to Announce Third Quarter 2026 Financial Results November 2nd
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
The Top HealthTech Questions Landing on Our Desks
2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right.